TPGS-enabled micellar encapsulation significantly enhances the oral delivery profile of CAB, offering a promising, non-invasive, and patient-compliant alternative to parenteral antiretroviral regimens, potentially improving therapeutic outcomes in HIV management.
Vernekar et al. (Tue,) studied this question.